ClinicalTrials.Veeva

Menu

Safety and Performance Evaluation of CPB Venous and Arterial Cannulas

E

Eurosets

Status

Enrolling

Conditions

Heart Surgery
Arterial Cannulation
Cardiac Surgery
Venous Cannulation
Coronary Surgery
Aortic Valve Surgery
Cardiopulmonary Bypass
Coronary Surgery With Cardiopulmonary Bypass
Cannulation

Treatments

Device: Control Arterial and Venous Cannulas
Device: Eurosets Venous and Arterial Cannula

Study type

Interventional

Funder types

Industry

Identifiers

NCT07354841
DE-62-22
CIV-IT-25-03-051856 (Other Identifier)

Details and patient eligibility

About

This is a two-phase study evaluating the Eurosets arterial and venous cannulas for use during cardiopulmonary bypass (CPB) procedures. Phase 1 is a pilot study focused on assessing cannula safety. Phase 2 is a pivotal study aimed at confirming safety and evaluating efficacy through comparison with Medtronic cannulas (control group).

The results will be compared for non-inferiority with those obtained using the control group cannulas.

Full description

The Clinical Investigation is a Two Phases clinical investigation consisting of a pre-Market, Pilot, Interventional, not Randomized, Monocentric Investigation to Evaluate the Safety of PVC Arterial Cannula and PVC Venous Cannula (Class III Medical Devices) intended to be used during Cardiopulmonary Bypass (CPB) procedure followed by a pre-Market, Pivotal, Interventional, Randomized, Non- inferiority, Monocentric Investigation to confirm the Safety and evaluate the Performance of the same cannulas.

The aim of these investigations are: 1) to evaluate safety of Eurosets Venous Cannula and Arterial Cannula in patients subjected to CPB and 2) to evaluate the performance and safety of Arterial Cannula and Venous Cannula intended to be used during CPB procedure. The results obtained will be compared by non-inferiority to the results obtained by Medtronic cannulae (control group).

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient is considered able and willing to provide written informed consent according to the ethically approved informed consent form;
  2. Female and male patients aged ≥ 18;
  3. Body weight between 60 and 120 kg;
  4. Body surface area (BSA) between 1.5 and 2.5 m2;
  5. Patients scheduled to undergo central cannulation for cardiopulmonary bypass (CPB) in elective surgery procedures (isolated coronary and/or aortic valve surgery).

Exclusion criteria

  1. Emergency cases;
  2. Re-do cardiac surgery procedure;
  3. Diabetes mellitus;
  4. Hematologic diseases or history of thrombophilia;
  5. Pregnancy or breastfeeding;
  6. Concomitant major cardiac procedures;
  7. Active malignant/metastatic neoplasm of any type;
  8. Presence of pneumothorax and/or pulmonary emphysema;
  9. Significant central nervous system injury;
  10. Current intracranial hemorrhage;
  11. Immunosuppression;
  12. Contraindication for therapeutic anticoagulation (e.g., heparin);
  13. Anatomical and structural abnormalities which, in the opinion of the Investigator, may interfere with the participation to the study;
  14. Abnormal or pathological cannulation site;
  15. Uncontrolled active bleeding;
  16. Awaiting transplantation;
  17. Requiring preoperative extracorporeal membrane oxygenation;
  18. Presence of any relevant severe condition or clinically relevant abnormal laboratory parameters that in the opinion of the Investigator may interfere with the participation to the study.
  19. Patient is taking part in another interventional clinical study;
  20. Patient is not able to understand the nature of this study or is unwilling or unable to attend the EOS Visit.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

80 participants in 2 patient groups

Eurosets Arterial and Venous Cannula
Experimental group
Description:
Phase 1: All enrolled subjects will undergo cardiopulmonary bypass using the investigational Eurosets arterial and venous cannulas to evaluate the safety. Phase 2: Participants will undergo cardiopulmonary bypass using the investigational Eurosets arterial and venous cannulas to confirm safety and to evaluate the performance.
Treatment:
Device: Eurosets Venous and Arterial Cannula
Control Arterial and Venous Cannula
Active Comparator group
Description:
Phase 2: Participants will undergo cardiopulmonary bypass using commercially available arterial and venous cannulas currently used in standard clinical practice.
Treatment:
Device: Control Arterial and Venous Cannulas

Trial contacts and locations

1

Loading...

Central trial contact

Prof. Giuseppe Nasso

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems